Treating breast cancer drug resistance via a malaria drug

Share this content:

the ONA take:

The drug hydroxychloroquine (HCQ) was originally creasted to treat malaria, and is also used to treat patients with lupus and arthritic conditions. Researchers, in a study published in Clinical Cancer Research, shared results that showed that HCQ may have an effect reversing resistance to the popular breast cancer drug tamoxifen. Nearly half of the women treated with tamoxifen for their breast cancer either do not respond to the drug or become resistant to it, so this may represent a way to lower that percentage. In their study, the researchers spliced tumors containing postmenopausal estrogen receptor-positive (ER+) breast cancer into mice and examined the results. Some women become resistant to tamoxifen because a "pro-survival" cell pathway become active, and HCQ can deactivate this pathway and thereby decrease tamoxifen resistance.

Treating breast cancer drug resistance via a malaria drug
Treating breast cancer drug resistance via a malaria drug
An inexpensive malaria drug could be the answer for some women who are not responding to their cancer treatment, according to a promising but preliminary animal study. In a recent study published in Clinical Cancer Research, researchers discovered the anti-malaria drug hydroxychloroquine (HCQ) can actually reverse drug resistance to the common breast cancer drug, tamoxifen.
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs